While MET exon 14 skipping transcripts have not previously been reported in primary UMs, there is emerging evidence of cMET protein overexpression in primary and metastatic UM [25], indicating a promising therapeutic target for patients with metastatic disease. The gene discussed is MET; the disease is metastatic neoplasm.